Prevention of Pegfilgrastim-Induced Bone Pain (PIBP) - Full Text View

Purpose

RATIONALE: Naproxen may help prevent or lessen bone pain caused by pegfilgrastim. It is not yet known whether naproxen is more effective than a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy.

PURPOSE: This randomized phase III trial is studying naproxen to see how well it works compared with a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy.

Condition	Intervention	Phase
Musculoskeletal Complications Pain Unspecified Adult Solid Tumor, Protocol Specific	Drug: naproxen Other: placebo	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Supportive Care
Official Title:	Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial

Resource links provided by NLM:

Drug Information available for: Naproxen Naproxen sodium Pegfilgrastim

U.S. FDA Resources

Further study details as provided by University of Rochester:

Primary Outcome Measures:

Severity and duration of bone pain (day 1 being the day pegfilgrastim is administered) as measured by a daily diary [ Time Frame: from baseline through day 5 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Potential risk factors for the development of pegfilgrastim-induced bone pain [ Time Frame: at time of onstudy ] [ Designated as safety issue: No ]
Potential clinical predictors for response or failure to respond to treatment [ Time Frame: at enrollment ] [ Designated as safety issue: No ]
Presence or severity of symptoms [ Time Frame: at enrollment and at off study-5 days ] [ Designated as safety issue: No ]


Enrollment:	512
Study Start Date:	June 2008
Estimated Study Completion Date:	November 2014
Estimated Primary Completion Date:	June 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Arm I Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.	Drug: naproxen Oral naproxen twice daily for 5-8 days.
Placebo Comparator: Arm II Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.	Other: placebo Oral placebo twice daily for 5-8 days.

Detailed Description:

OBJECTIVES:

Primary

To compare the efficacy of daily administration of naproxen vs placebo in preventing or reducing the severity and duration of pegfilgrastim-induced bone pain (PIBP) in patients with non-hematologic malignancies undergoing chemotherapy.

Secondary

To identify potential risk factors for the development of PIBP.
To identify potential clinical predictors for the response or failure to respond to naproxen in preventing PIBP.
To assess the toxicity of naproxen when administered in the preventive setting.

OUTLINE: This is a multicenter study. Patients are stratified by CCOP site. Patients are randomized to 1 treatment arm vs placebo.

Arm I: Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
Arm II: Patients receive matching placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of a non-hematologic (non-myeloid) malignancy
Scheduled to receive chemotherapy
- Chemotherapy may be given for adjuvant, neoadjuvant, curative, or palliative intent
Scheduled to receive the first dose of pegfilgrastim (Neulasta®) to ameliorate chemotherapy-induced neutropenia

PATIENT CHARACTERISTICS:

Not pregnant or nursing
Creatinine ≤ 1.5 times upper limit of normal
Able to understand English
No clinical evidence of active gastrointestinal bleeding, prior gastrointestinal bleeding, or gastric or duodenal ulcers
No known allergy to naproxen
No prior development of the triad of asthma, rhinitis, and nasal polyps after taking acetylsalicylic acid (aspirin) or other NSAIDs

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
More than 6 months since prior surgery on the heart
No concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, or any product containing naproxen (e.g., Naprosyn, EC-Naprosyn, Anaprox, Anaprox-DS, Naprosyn suspension, or Aleve), on a regular basis
No concurrent steroids on a regular basis
No concurrent prescription or non-prescription medications for preexisting chronic pain
- Concurrent cardioprotective doses (≤ 325 mg/day) of aspirin allowed
No concurrent therapeutic doses of warfarin

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00602420

Locations


United States, Hawaii
MBCCOP - Hawaii
Honolulu, Hawaii, United States, 96813
United States, Illinois
CCOP - Central Illinois
Decatur, Illinois, United States, 62526
CCOP - Evanston
Evanston, Illinois, United States, 60201
United States, Kansas
CCOP - Wichita
Wichita, Kansas, United States, 67214-3882
United States, Michigan
CCOP - Grand Rapids
Grand Rapids, Michigan, United States, 49503
United States, Minnesota
CCOP - Metro-Minnesota
St. Louis Park, Minnesota, United States, 55416
United States, Missouri
CCOP - Kansas City
Kansas City, Missouri, United States, 64131
United States, New York
CCOP - Hematology-Oncology Associates of Central New York
Syracuse, New York, United States, 13215
United States, North Carolina
CCOP - Southeast Cancer Control Consortium
Goldsboro, North Carolina, United States, 27534-9479
United States, Ohio
CCOP - Columbus
Columbus, Ohio, United States, 43215
CCOP - Dayton
Dayton, Ohio, United States, 45429
United States, South Carolina
CCOP - Greenville
Greenville, South Carolina, United States, 29615
CCOP - Upstate Carolina
Spartanburg, South Carolina, United States, 29303
United States, Washington
CCOP - Virginia Mason Research Center
Seattle, Washington, United States, 98101
CCOP - Northwest
Tacoma, Washington, United States, 98405-0986
United States, Wisconsin
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin, United States, 54449

Sponsors and Collaborators

Gary Morrow

National Cancer Institute (NCI)

Investigators


Study Chair:	Jeffrey J. Kirshner, MD	CCOP - Hematology-Oncology Associates of Central New York
Study Chair:	Gary R. Morrow, PhD, MS	University of Rochester
Study Chair:	Jeffrey K. Giguere, MD, FACP	CCOP - Greenville

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided


Responsible Party:	Gary Morrow, Director, URCC CCOP Research Base, University of Rochester
ClinicalTrials.gov Identifier:	NCT00602420 History of Changes
Other Study ID Numbers:	CDR0000584341, U10CA037420, URCC-07079
Study First Received:	January 22, 2008
Last Updated:	January 31, 2014
Health Authority:	United States: Federal Government

Keywords provided by University of Rochester:


pain musculoskeletal complications unspecified adult solid tumor, protocol specific

ClinicalTrials.gov processed this record on March 03, 2015